New Psoriasis Drug Shows Promising Results Say Johnson And Johnson
Centocor Inc, a subsidiary of drug company Johnson & Johnson have announced that international phase 3 trials for its injectable biologic drug to treat psoriasis, CNT0 1275 (ustekinumab), have shown promising results.According to the National Institutes of Health, some 7.5 million Americans have psoriasis, a non-contagious, lifelong skin disease.
